
Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – HC Wainwright increased their Q4 2027 EPS estimates for Unicycive Therapeutics in a research note issued on Tuesday, November 17th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.07 for the quarter, up from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.05) per share.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.10.
Get Our Latest Stock Analysis on Unicycive Therapeutics
Unicycive Therapeutics Stock Down 1.1%
Shares of NASDAQ:UNCY opened at $3.53 on Wednesday. Unicycive Therapeutics has a 52 week low of $3.33 and a 52 week high of $8.74. The stock has a market capitalization of $103.01 million, a P/E ratio of -2.11 and a beta of 1.91. The firm has a fifty day simple moving average of $4.07 and a two-hundred day simple moving average of $5.88.
Institutional Investors Weigh In On Unicycive Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in Unicycive Therapeutics by 80.8% in the third quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after purchasing an additional 117,463 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Unicycive Therapeutics during the first quarter valued at approximately $940,000. Seven Fleet Capital Management LP raised its holdings in shares of Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after buying an additional 47,700 shares during the period. Virtu Financial LLC raised its holdings in shares of Unicycive Therapeutics by 412.4% in the third quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock worth $279,000 after buying an additional 47,874 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Unicycive Therapeutics during the 2nd quarter worth approximately $248,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.
More Unicycive Therapeutics News
Here’s some of the latest news about UNCY:
- Positive Sentiment: HC Wainwright raised its loss-per-share estimates for 2026 and each of Q4 2026 through Q3 2027, including its FY2027 forecast to ($0.71) from ($0.86). The analyst maintained a Buy rating and a $13 price target, providing a bullish counterpoint to the stock’s recent weakness. MarketBeat UNCY coverage
- Neutral Sentiment: Brookline Capital Markets issued forecasts showing substantial future profits, including $3.93 EPS for FY2027 and $3.33 for FY2030. These are new estimates rather than revisions, and differ significantly from HC Wainwright’s outlook, highlighting uncertainty around the company’s longer-term earnings potential. MarketBeat UNCY coverage
- Negative Sentiment: HC Wainwright cut its FY2028–FY2030 EPS forecasts, including reducing FY2030 from $4.98 to $2.59. Noble Financial also raised its projected losses for Q4 and FY2026, forecasting FY2026 EPS of ($0.80) versus its prior ($0.62). These revisions temper the more favorable near-term outlook. MarketBeat UNCY coverage
About Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Recommended Stories
- Five stocks we like better than Unicycive Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
